Search Results
Your search for James B. Yu, MD matches 26 pages
Showing 1 - 26Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
ASTRO Names FASTRO Recipients for 2023
A total of 29 distinguished members of the American Society for Radiation Oncology (ASTRO) have been named Fellows of ASTRO. The ASTRO Fellow designation, FASTRO, honors individuals who have contributed significantly to the Society through committee work, other volunteer service, and to the field...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. A complete list of individuals...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. Here is a complete list of...
RELATIVITY-047: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
In the recently published results of the RELATIVITY-047 trial,1 summarized in this issue of The ASCO Post, the addition of relatlimab to nivolumab monotherapy was associated with improved progression-free survival compared with nivolumab alone in patients with previously untreated advanced,...
Narratives in Oncology Through the Years
Beginning in 2012,The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. A complete list of individuals...
Conquer Cancer Announces 2020 Quality Care Symposium Merit Awards
Conquer Cancer, the ASCO Foundation® is pleased to announce the recipients of its 2020 Quality Care Symposium Merit Awards. These distinguished awards recognize oncology fellows and trainees who are first authors on top-ranking abstracts selected for presentation at the virtual ASCO Quality Care...
Conquer Cancer Honors Early-Career Cancer Researchers With Merit Awards
ASCO and Conquer Cancer, the ASCO Foundation®, congratulate the recipients of recent Conquer Cancer Merit Awards, which recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to an ASCO-sponsored or cosponsored meeting. These early-career researchers presented their...
ASCO Presidents Through the Years: Past, Present, and Future
2020–2021: Lori J. Pierce, MD, FASTRO 2019–2020: Howard “Skip” Burris, III, MD, FACP 2018–2019: Monica M. Bertagnolli, MD 2017–2018: Bruce E. Johnson, MD 2016–2017: Daniel F. Hayes, MD 2015–2016: Julie Vose, MD, MBA 2014–2015: Peter P. Yu, MD 2013–2014: Clifford A. Hudis, MD 2012–2013: Sandra M....
Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting
Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...
Emergency Department Visits for Treatment-Related Complications of Systemic Therapy and Radiotherapy
In a study reported in JAMA Oncology, Jairam et al found that emergency department visits for complications of systemic therapy or radiotherapy in patients with cancer increased at a 5.5-fold higher rate over 10 years compared with overall emergency department visits. Study Details The study...
ASCO Through the Years: Past Presidents
Over the years many great oncology leaders have served at the helm as ASCO President. We recognize these individuals here, and extend our gratitude for their service and efforts to champion high-quality cancer care. 2018-2019: Monica M. Bertagnolli, MD 2017-2018: Bruce E. Johnson, MD 2016-2017:...
ASCO Presidents Through the Years
2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...
Celebrating ASCO 2016 Awards Recipients
Peter Paul Yu, MD, FACP, FASCO, Immediate Past President of ASCO and Chair of the Special Awards Selection Committee, announced the recipients of this year’s special awards. “The exceptional accomplishments of each of our awardees reflect their exemplary dedication to furthering cancer research and ...
James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer
James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).
Novel Agents for Breast Cancer and Prostate Cancer Impressive in Early Trials
Several sessions at the 2012 European Society for Medical Oncology (ESMO) Congress in Vienna focused on novel targeted therapies in various stages of development. Summarized here are data on two promising drugs for breast cancer and two for prostate cancer. E-3810 in Breast Cancer Two experimental...
Early Quality of Life Better with Proton-beam Therapy, but Late Effects Similar to Other Treatment Modalities for Prostate Cancer
Differing patterns of patient-reported quality of life for three-dimensional (3D) conformal radiotherapy, intensity-modulated radiation therapy, and proton-beam therapy were reported in a nonrandomized comparison of three modern cohorts of patients with prostate cancer. The study was presented at...
No Difference in Toxicity with Proton Radiotherapy vs Less Costly Intensity-modulated Radiotherapy
A national sample of Medicare beneficiaries treated for prostate cancer with intensity-modulated radiation therapy or proton radiotherapy found that proton radiotherapy “was rare and expensive and associated with only a modest and transient reduction in genitourinary toxicity,” reported James B....
Ongoing Clinical Trials Actively Recruiting Patients With Gastrointestinal Cancers
This Clinical Trials Resource Guide is meant to increase awareness of currently recruiting NCI- or academic institution–sponsored clinical studies for your patients with gastrointestinal cancers. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov, and...
Genitourinary Toxicity More Likely With Stereotactic Body Radiotherapy Than With Intensity-Modulated Radiotherapy
A retrospective analysis of patients with prostate cancer receiving primary treatment with either stereotactic body radiation therapy or intensity-modulated radiation therapy found that those receiving stereotactic body radiotherapy had greater rates of genitourinary toxicity during 2-year...
ASCO Through the Years: Past Presidents
This year ASCO celebrates it's 50th Anniversary. Here is a list of past ASCO Presidents over these 50 years: 2014-2015: Peter P. Yu, MD 2013-2014: Clifford A. Hudis, MD 2012-2013: Sandra M. Swain, MD, FACP 2011-2012: Michael P. Link, MD 2010-2011: George W. Sledge, Jr, MD 2009-2010: Douglas W....
2014 Featured Columnists
The ASCO Post wishes to acknowledge and thank all contributors to the publication during 2014. Here we recognize those who shared their personal thoughts in our Op-Ed department. If you are interested in contributing to The ASCO Post in 2015, write to editor@ASCOPost.com. Robert Peter Gale, MD,...
Simple Means of Preventing Nonmelanoma Skin Cancer Reported
Two daily doses of nicotinamide, a form of vitamin B3, significantly reduced the occurrence of nonmelanoma skin cancers by 23% in individuals considered at high risk for these lesions in an Australian study. Results of the phase III ONTRAC trial, which will be presented at the 2015 ASCO Annual...
Quick Takes From ECC 2015 Include New Data in Melanoma, Prostate and Breast Cancers, and Renal Cell Carcinoma
The 2015 European Cancer Congress (ECC), held recently in Vienna, represented the combined efforts of the European Cancer Organisation (ECCO), the European Society for Medical Oncology (ESMO), and other partner organisations, constituting the largest European platform for oncology education. At...
Low Use of Decision Aids for Localized Prostate Cancer by Radiation Oncologists and Urologists
In a survey study reported in JAMA Internal Medicine, Wang et al found that a minority of responding radiation oncologists and urologists used decision aids for localized prostate cancer in clinical practice. Study Details In the study, a survey regarding use of and attitudes toward decision aids ...
Stereotactic Body Radiation Costs Less but Is Associated With More Genitourinary Toxicity vs Intensity-Modulated Radiation Therapy for Prostate Cancer
In a retrospective Medicare-based study reported in the Journal of Clinical Oncology, Yu et al found that although stereotactic body radiation therapy is associated with lower treatment costs than intensity-modulated radiation therapy in treatment of prostate cancer, it is also associated with...
